Introduction
Sickle cell disease (SCD) is a hemolytic anemia that is inherited in an autosomal recessive fashion, based on a single-point mutation in the gene encoding for the β-globin chain of hemoglobin (Hb). 1 It is an extremely common monogenetic disease worldwide, affecting an estimated 1% to 4% of infants born in Sub-Saharan Africa 2 and approximately 1 in 500 African Americans.
Rapid-onset bronchodilators are medications used to relax airway smooth muscle and thereby provide rapid symptom relief in the setting of bronchoconstriction. This class of medications includes short-acting β-adrenergic receptor agonists such as albuterol and terbutaline, which act by binding to the β-2 adrenergic receptors on bronchial smooth muscle, 16 as well as the anticholinergic agent ipratropium bromide, which is a muscarinic receptor antagonist. 17 While bronchodilators have been reported to improve forced expiratory volume in 1 second in a proportion of subjects with ACS and reactive airways disease, 6 their ability to improve other clinical outcomes are unknown. A recent Cochrane review found no randomized controlled trials evaluating bronchodilators for ACS. 18 Our primary aim was to examine the variability in rapid-onset bronchodilator use for ACS among pediatric hospitals. We hypothesized that there would be a large amount of variability, reflecting the paucity of clinical evidence to guide best practice. Our secondary aim was to examine the relationship between rapid-onset bronchodilator use for ACS and outcomes including length of hospital stay and mortality.
Methods

Description of the Database
Data for this retrospective analysis were obtained from the Pediatric Health Information System (PHIS), an administrative database that contains inpatient, emergency department, ambulatory surgery, and observation data from 43 not-for-profit, tertiary care pediatric hospitals in the United States. These hospitals are affiliated with the Children's Hospital Association (Overland Park, KS). Data quality and reliability are assured through a joint effort between the Children's Hospital Association and participating hospitals. The data warehouse function for the PHIS database is managed by Truven Health Analytics (Ann Arbor, MI). For the purposes of external benchmarking, hospitals provide discharge/encounter data including demographics, diagnoses, and procedures and resource utilization data (eg, pharmaceuticals, imaging, and laboratory) into PHIS. Data are de-identified at the time of data submission and are subjected to a number of reliability and validity checks before being included in the database. For this study, pharmacy data for hospitalizations that met our case definition were available from 43 hospitals. For a subgroup analysis of hospitalizations with a co-diagnosis of asthma, data were available from 41 hospitals.
This study was approved by the Institutional Review Board of Boston Children's Hospital.
Case Definition
We included all cases of ACS aged 0 to 21 Variability in Bronchodilator Use. The unit of analysis was each distinct hospitalization. The primary outcome was any use of bronchodilator during the hospitalization, including inhaled albuterol sulfate, levalbuterol HCl, ipratropium bromide, albuterol sulfate and ipratropium bromide, or parenteral terbutaline sulfate. We examined the variability between hospitals in the use of any bronchodilator among their respective ACS patients. We standardized each hospital's use of bronchodilators for ACS by adjusting for the hospital case mix (a relative value indicating the average complexity or severity of illness in each hospital relative to the other hospitals). We examined variability in bronchodilator use for the entire cohort as well as the subgroup of hospitalizations for which there was a co-diagnosis of asthma (defined as ICD-9 codes 493, 493.01, 493.02, 493.1, 493.11, 493.12, 493.9, 493.91, or 493.92). We also examined variability in bronchodilator use in the subgroup whose primary diagnosis was defined as sickle cell crisis and ACS (not pneumonia), to ensure that our findings were not dependent on our case definition.
Length of Stay.
To examine length of stay, the unit of analysis was each distinct hospitalization. Because length of stay was highly positively skewed, we employed a Poisson regression to evaluate the association between bronchodilator use and length of stay. Generalized estimating equations were utilized to account for clustering of multiple hospitalizations per patient. A comprehensive model was made. Potential confounders, comprising multiple indicators of disease severity and acuity, were determined a priori based on clinical concern and previous literature.
These included subject-level covariates (age, gender, race, HbSS genotype, primary insurance payer, and diagnosis of asthma), treatments associated with asthma (inhaled steroids and systemic steroids), treatments during the hospitalization that could act as markers of severity of acute and/or chronic illness (use of narcotics, antibiotics, oxygen, mechanical ventilation, blood transfusion, inhaled nitric oxide, and hydroxyurea, and admission to an intensive care unit), other markers of severity (subject having ⩾3 admissions for sickle cell crisis in the last year and the All Patient Refined Diagnosis Related Groups [APRDRGs] severity subclass, a 4-point scale indicating severity of illness, with higher level indicating more severe illness), and hospital-level covariates (discharge year to account for changes in practice over time, and average number of admissions for SCD per year to account for hospital experience with the disease).
Subgroup Analysis. We repeated the Poisson regression analysis in the subgroups of patients with and without a comorbid ICD-9 diagnosis of asthma (as defined above), in order to verify whether the association between bronchodilator use and length of stay was different in these populations.
Mortality. We used a χ 2 test to evaluate the association between bronchodilator use and mortality. Since this outcome was extremely rare in this cohort, we did not estimate a multivariate model. Therefore, the unadjusted odds ratio is presented.
Analyses were conducted using IBM SPSS statistics version 19.0.
Results
Characteristics of Hospitalizations
There were 11 328 hospitalizations (5903 individual subjects) that met our case definition across the 43 hospitals. The mean number of cases of ACS per hospital was 300.0 (standard deviation = 200.3). Bronchodilators were used in 60.1% of hospitalizations, and albuterol was the most frequently prescribed bronchodilator. There were 792 hospitalizations (7.0%) with a co-diagnosis of asthma, of which bronchodilators were used in 704 cases. Table 1 shows the characteristics of the hospitalizations for the entire cohort, subdivided by bronchodilator use. The group that received bronchodilators was statistically significantly more likely to be male, black, have the HbSS genotype, require admission to an intensive care unit, have more severe disease (APRDRGs severity subclass 4), have a diagnosis of asthma, receive inhaled or systemic steroids, and other treatments related to ACS (Table 1) .
Variability in Bronchodilator Use
The likelihood of receiving bronchodilators, after adjusting for the average case mix of the entire cohort, ranged from 0.0% to 97.0% (median = 46.0%, interquartile range (IQR) = 37.0% to 74.0%; Figure 1 ). Similar results were obtained when the analysis was performed using only those cases defined using ICD-9 codes for sickle cell crisis and ACS (excluding cases defined using pneumonia codes), with a range of 0.0% to 98.0%, median = 50.4%, and IQR = 37.6% to 76.4%.
When limiting the analysis to hospitalizations of patients with a co-diagnosis of asthma (N = 792 hospitalizations among 41 hospitals), the variability ranged from 0.0% to 100.0%, but with a median of 98.2% and IQR = 73.7% to 100.0%, suggesting more frequent use.
Bronchodilator Use and Length of Stay
The median length of stay for the entire cohort was 4 days, IQR = 2 to 6 days. In the unadjusted model, bronchodilator use was associated with a 24.4% increase in length of stay (95% confidence interval [CI] 19.7% to 29.4%, P < .001). In the adjusted model, bronchodilator use was associated with an expected 13.2% increase in length of stay (95% CI = 9.2% to 17.3%, P <.001; Table 2 ).
Subgroup Analysis
When confining the analysis to subjects without comorbid asthma, the expected length of stay remained increased by 14.5% in the group that received bronchodilators (95% CI = 10.5% to 18.6%, P < .001). However, when confining the analysis to subjects with comorbid asthma, bronchodilator use was associated with a decrease in expected length of stay by 17.9% (95% CI = 1.7% to 31.4%, P = .03).
Bronchodilator Use and Mortality
Mortality was very rare (N = 11, corresponding to 0.1% of the cohort). There was no difference in mortality between the group that received bronchodilators (n = 7, 0.1%) versus the group that did not receive bronchodilators (n = 4, 0.1%).
Discussion
We demonstrate that there is high variability in the use of bronchodilators during admissions for ACS among large pediatric hospitals in North America, ranging from 0.0% to 97.0%. We also report that bronchodilator use during admissions for ACS is associated with longer length of hospital stay, after adjusting for multiple potential confounders. However, in the subcohort of patients with a co-diagnosis of asthma, bronchodilator use is associated with a decreased length of stay. Bronchodilator use is not associated with mortality, which is a very rare outcome in this population. This is the first study that we are aware of to report on variability in bronchodilator use, as well as the association between bronchodilator use and length of stay for ACS. The high variability we found in the use of bronchodilators for ACS likely reflects the dearth of published evidence regarding their efficacy in the SCD population 18 as well as conflicting expert recommendations. Some authors suggest using bronchodilators only in patients with a known history of asthma or as a trial in those who are wheezing on physical examination, 20 while others recommend that AHR should be assumed to be present in all patients and bronchodilators should be used universally. 6 Not surprisingly, our analysis shows that among patients with a co-diagnosis of asthma, there was less variability in bronchodilator use and a greater proportion of patients received bronchodilators during the admission for ACS (median = 98.2%). The increased use of bronchodilators in this population may be explained by the known association between patients with SCD and comorbid asthma and higher rates of pain crisis 4 and higher risk of death, 21 which may prompt initiation of bronchodilator treatment more readily.
Our results show that bronchodilator use is associated with a modest increase in length of hospital stay for patients admitted with ACS. It is possible that the adverse effects of bronchodilators such as tachycardia, anxiety, and hyperactivity 18 may be contributing to a longer length of stay. In subgroup analysis, we found that length of stay was increased with bronchodilator use among subjects who did not have a co-diagnosis of asthma; however, in subjects with a co-diagnosis of asthma, bronchodilator use was associated with a decreased length of stay. This suggests that bronchodilators may be effective during ACS only in those patients with asthma and actually are potentially harmful in patients without asthma. However, caution should be taken in interpreting this finding as it may be a result of confounding by indication. Bronchodilator use was associated with multiple measures of severity and sicker patients tend to receive more medication, including bronchodilators. We attempted to control for severity of illness using 2 possible confounders (APR-DRGs score and ⩾3 admissions for sickle cell crisis in the last year) as well as multiple other measures of disease severity, including requirement for mechanical ventilation and intensive care unit admission, but there may be remaining unmeasured confounders that we were unable to assess given the nature of the dataset. This needs to be clarified with prospective studies in the future.
It should be noted that the increased length of stay of 13.2%, while statistically significant, may not be clinically significant because it represents an estimated increase of approximately only 5 hours. However, the fact that this association held up when looking at the subpopulation of patients without asthma, and that a statistically significant decrease in length of stay was identified among those patients with asthma, provides convincing evidence of a signal in these data. Perhaps other severity outcomes, such as oxygenation and lung function, which were impossible to evaluate in this Our study has several strengths. By using a large database encompassing data from multiple hospitals across North America, we were able to capture a very large number of hospitalizations (>11 000). We were also able to control for a large number of potential confounders in our models.
The nature of this study presents a few potential limitations. The PHIS database is collected for administrative purposes and not for clinical research; therefore, there may be errors in coding that caused us to miss cases of ACS. However, we accounted for this by defining cases as those with a diagnosis of either ACS or pneumonia in an effort to include all with an infiltrate on chest radiograph. The PHIS database also provides data on billed services and pharmaceutical codes, but this does not necessarily equate to administered services and treatments. Finally, while we attempted to control for various measures of severity, acuity, and co-diagnosis of asthma, it is impossible to completely eliminate the possibility of confounding by indication with a retrospective analysis. 
Conclusion
There is wide variability in bronchodilator use during hospitalizations for ACS in patients with SCD. Bronchodilator use for ACS may be associated with longer length of stay but not with mortality. The finding of an association between bronchodilator use and longer length of stay in our study may indicate that bronchodilators are potentially harmful in this population, but it is also possible that this finding was secondary to confounding by indication. Interestingly, bronchodilator use is associated with shorter length of stay among patients with a co-diagnosis of asthma, suggesting this subpopulation likely benefits from their use during admissions for ACS. There is sufficient uncertainty and clinical equipoise to justify a randomized, double-blinded, placebo-controlled trial to establish whether bronchodilators are effective and safe for use during ACS. Such a trial is needed to help inform clinical practice.
